Abbott to update CardioMEMS to allow patients to track pulmonary artery pressure
The FDA approved an update to Abbott’s (NYSE: ABT) heart failure monitoring platform, which will […]
The FDA approved an update to Abbott’s (NYSE: ABT) heart failure monitoring platform, which will allow patients to view their implant’s readings and receive personalized medication updates through an app.
Abbott’s CardioMEMS system includes a wireless blood pressure sensor placed within the pulmonary artery, to catch early signs of worsening heart failure. Previously any changes were monitored remotely by clinicians, who could then adjust medication doses or make lifestyle recommendations.
By using the company’s CardioGuide HF smartphone app, patients will be able to track their own pulmonary artery pressure trends and receive new drug regimens through a pre-established dynamic treatment plan.
Read full article: https://www.massdevice.com/abbott-to-update-cardiomems-to-allow-patients-to-track-pulmonary-artery-pressure/